[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2001083700A3 - Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal - Google Patents

Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal Download PDF

Info

Publication number
WO2001083700A3
WO2001083700A3 PCT/US2001/014080 US0114080W WO0183700A3 WO 2001083700 A3 WO2001083700 A3 WO 2001083700A3 US 0114080 W US0114080 W US 0114080W WO 0183700 A3 WO0183700 A3 WO 0183700A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacteria
gram
gastro
composition
intestinal
Prior art date
Application number
PCT/US2001/014080
Other languages
French (fr)
Other versions
WO2001083700A2 (en
Inventor
Pinaki Panigrahi
Original Assignee
Univ Maryland
Pinaki Panigrahi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland, Pinaki Panigrahi filed Critical Univ Maryland
Priority to US10/275,171 priority Critical patent/US20040096427A1/en
Priority to EP01937205A priority patent/EP1292189A4/en
Priority to CA002407724A priority patent/CA2407724A1/en
Priority to AU2001262966A priority patent/AU2001262966A1/en
Publication of WO2001083700A2 publication Critical patent/WO2001083700A2/en
Publication of WO2001083700A3 publication Critical patent/WO2001083700A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A composition and method for treating and preventing gastro-intestinal injury are disclosed. The composition includes a combination of Gram (+) bacteria, in particular ∫i⊃Lactobacillus∫/i⊃ and/or ∫i⊃Bifidobacteria∫/i⊃, and glutamine. The method involves orally or naso-gastrically administering a composition containing Gram (+) bacteria, in particular ∫i⊃Lactobacillus∫/i⊃, and glutamine. The composition, which blocks translocation of bacterial agents such as Gram (-) bacteria, other infectious agents, toxins, chemicals and injurious substances, may be used in the prevention and treatment of symptoms and/or disease that result from translocation of Gram (-) bacteria, including inflammation in the gastro-intestinal tract, Neonatal Necrotizing Enterocolitis (NEC) and bacterial sepsis.
PCT/US2001/014080 2000-05-03 2001-05-03 Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal WO2001083700A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/275,171 US20040096427A1 (en) 2001-05-03 2001-05-03 Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal dysfunctions including inflammation in the gastro-intestinal tract, neonatal necrotizing enterocolitis (nec) and bacterial sepsis
EP01937205A EP1292189A4 (en) 2000-05-03 2001-05-03 Oral gram (+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal
CA002407724A CA2407724A1 (en) 2000-05-03 2001-05-03 Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal
AU2001262966A AU2001262966A1 (en) 2000-05-03 2001-05-03 Oral gram (+) bacteria and glutamine composition for prevention and/or treatmentof gastro-intestinal dysfunctions including inflammation in the gastro-intestin al tract, neonatal necrotizing enterocolitis (nec) and bacterial sepsis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20140800P 2000-05-03 2000-05-03
US60/201,408 2000-05-03

Publications (2)

Publication Number Publication Date
WO2001083700A2 WO2001083700A2 (en) 2001-11-08
WO2001083700A3 true WO2001083700A3 (en) 2002-02-07

Family

ID=22745700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014080 WO2001083700A2 (en) 2000-05-03 2001-05-03 Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal

Country Status (4)

Country Link
EP (1) EP1292189A4 (en)
AU (1) AU2001262966A1 (en)
CA (1) CA2407724A1 (en)
WO (1) WO2001083700A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114419D0 (en) * 2001-06-13 2001-08-08 Mars Uk Ltd Health food
SE526711C2 (en) 2003-01-31 2005-10-25 Probi Ab Novel strains of Bifidobacterium having ability to survive in intestinal tract and produce glutamine and arginine in vivo, useful for preparing medicament for treatment of intensive care patients with intestinal failure

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707353A (en) * 1995-12-21 1998-01-13 Abbott Laboratories Oral administration of beneficial agents
US5755688A (en) * 1995-01-13 1998-05-26 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
US5981590A (en) * 1997-03-17 1999-11-09 Probiotix, Inc. Oral glutamine in the prevention of neonatal necrotizing enterocolitis and other gastrointestinal mucosal damage
US6007808A (en) * 1995-06-23 1999-12-28 Dibra S.P.A. Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6262019B1 (en) * 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5755688A (en) * 1995-01-13 1998-05-26 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
US6007808A (en) * 1995-06-23 1999-12-28 Dibra S.P.A. Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
US5707353A (en) * 1995-12-21 1998-01-13 Abbott Laboratories Oral administration of beneficial agents
US5981590A (en) * 1997-03-17 1999-11-09 Probiotix, Inc. Oral glutamine in the prevention of neonatal necrotizing enterocolitis and other gastrointestinal mucosal damage
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6262019B1 (en) * 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1292189A4 *

Also Published As

Publication number Publication date
EP1292189A4 (en) 2003-08-13
WO2001083700A2 (en) 2001-11-08
CA2407724A1 (en) 2001-11-08
AU2001262966A1 (en) 2001-11-12
EP1292189A2 (en) 2003-03-19

Similar Documents

Publication Publication Date Title
Carson et al. Non-antibiotic therapies for infectious diseases
HK1009243A1 (en) Phosphate-binding polymers for oral administration
HK1041208B (en) Preparation which contains oligosaccharides and probiotics
Marbaix et al. Helicobacter Pylori and Periodontal diseases: An update and proposal of a multidisciplinary clinical protocol
WO2002007533A3 (en) Nutritional composition
MXPA02010322A (en) Methods for prevention and treatment of gastrointestinal disorders.
DE69622855D1 (en) PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN LACTOBACILLUS PLANTARUM AND ARGININE
HK1051490A1 (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs.
Drouin Helicobacter pylori: novel therapies
WO2003053474A3 (en) Use of micro-organisms for a directed delivery of substances to specific parts of the gut
WO2001083700A3 (en) Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal
Alveyn Antimicrobial prophylaxis daring biliary endoscopic procedures
WO2002040512A3 (en) Human beta-defensin-3
CA2330424A1 (en) Improved method for eradication of helicobacter pylori
Spadaccini et al. Omeprazole versus ranitidine: short‐term triple‐therapy in patients with Helicobacter pylori‐positive duodenal ulcers
Bayerdörffers et al. Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection
Nichols The role of quinolones in abdominal surgery
Kromann-Andersen et al. Ofloxacin in urinary tract infections
WO2000023058A3 (en) Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids
Lucey et al. Helicobacter pylori eradication is effective in preventing recurrent upper gastrointestinal bleeding in patients who use aspirin but not in those who use naproxen
IT1313628B1 (en) Use of gemifloxacin compounds, which can be active against bacterial strains resistant to other antibiotics, in treatment of infections caused by respiratory tract pathogenic bacteria
Watkins Tapered antibiotics with kefir may be effective in recurrent C. difficile infection.
WO2002019995A3 (en) Pharmaceutical combination containing salmeterol and fluticasone
MY114084A (en) Phosphate - binding polymers for oral administration
CA2590537A1 (en) The use of the neurotoxin component of a botulinum toxin for the treatment of excessive lacrimation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2407724

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001937205

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001937205

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10275171

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001937205

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP